Clinical Trial

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Study acronym: RePaIr-HN
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Prospective, open-label, randomized controlled phase III trail that aims to investigate whether Re-Radiochemotherapy (Re-RCT) and sequential immunotherapy with pembrolizumab improves overall survival compared to the standard treatment with pembrolizumab alone (± chemotherapy) in locoregionally recurrent PD-L1 positive (CPS≥1) HNSCC.
Protocol Amendment History 1 change
notable Trial sites expanded: 18 -> 21 locations 2026-07-24
Trial Details
NCT Number NCT07026474
Lead Sponsor Universität des Saarlandes
Conditions Recurrent Head and Neck Squamous Cell Carcinoma
Enrollment 214 participants
Start Date 2025-10-30
Primary Completion 2032-12 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-23